


Figure 1




Figure 2



Vehicle (PBS)
Compound A (5 mg/kg, HP-β-CD)
Compound A (10 mg/kg, HP-β-CD)
Compound 1 (10 mg/kg Compound A equiv, PBS)
Cleaved PARP concentration (pg/ug protein)
25000
20000
15000
10000
5000
0
1 3 9 20 48 72 1 3 9 20 48 72 1 3 9 20 48 72 1 3 9 20 48 72
Time (hr)

Figure 3



Vehicle
Vistusertib (AZD2014, 15 mg/kg, qd)
Compound 1 (103 mg/kg, 30 mg/kg Compound A equiv., qw)
Vistusertib (AZD2014) + Compound 1
Tumor Volume (mm3)
0
500
1000
1500
1
8
15
22
Day Post Dosing

Figure 4



Vehicle
Compound 1 (103 mg/kg, 30 mg/kg Compound A equiv., qw)
Acalabrutinib (12.5 mg/kg, bid)
Compound 1 + acalabrutinib
Dosing period
Tumor Volume (mm3)
GeoMean + SEM
1000
500
0
1
8
15
22
29
36
43
50
57
Days Post Dosing

Figure 5



Vehicle, iv, qw
Compound-1, (30mg/kg API, iv, qw)
Compound-1, (30mg/kg API, sc, qw)
Compound-1, (100mg/kg API, sc, qw)
Treatment
3 cycles
Tumor Volume (mm³)
GeoMean + SE
2000
1500
1000
500
0
50
60
70
80
Days post implant

Figure 6



Compound-1 (30mg/Kg API, IV, QW)
Compound-1 (30mg/Kg API, SC, QW)
Compound-1 (100mg/Kg API, SC, QW)
Plasma concentration
µM
1000
100
10
1
0
6
12
18
24
30
Time (hr)

Figure 7



Compound-1 (30mg/Kg API, IV, QW)
Compound-1 (30mg/Kg API, SC, QW)
Compound-1 (100mg/Kg API, SC, QW)
Tumor concentration
μM
100
10
1
0.1
0.01
0
6
12
18
24
30
Time (hr)

Figure 8



Percent CC3 induction
150
100
50
0
0.25
1.00
6.00
24.00
Time (hr)
Vehicle, IV
Compound-1
30mg/Kg API, IV
Compound-1
30mg/Kg API, SC
Compound-1
100mg/Kg API, SC

Figure 9